Adaptive Biotechnologies Corp (ADPT) Financials
Annual revenue, profitability and per-share results for Adaptive Biotechnologies Corp, as reported in SEC filings.
Revenue • FY2025
$276.98M
▲ 54.8%YoY
Net income • FY2025
-$59.5M
▲ 62.7%YoY
Gross margin • FY2025
74.2%
Diluted EPS • FY2025
$-0.39
▲ 63.9%YoY
Annual income statement
| Period | Revenue | Net income | Gross profit | Dil. EPS | Free cash flow | Op. margin | Rev. growth |
|---|---|---|---|---|---|---|---|
| FY2025 | $276.98M | -$59.5M | $205.62M | $-0.39 | -$48.95M | -20.6% | +54.8% |
| FY2024 | $178.96M | -$159.49M | $106.88M | $-1.08 | -$98.88M | -90.8% | +5.1% |
| FY2023 | $170.28M | -$225.25M | $94.72M | $-1.56 | -$167.02M | -133.3% | -8.1% |
| FY2022 | $185.31M | -$200.19M | $127.4M | $-1.40 | -$200.29M | -108.0% | +20.1% |
Figures as reported in Adaptive Biotechnologies Corp's 10-K filings on SEC EDGAR. Fiscal years may differ from calendar years.
Never miss a ADPT filing.
Get an email when ADPT files its next 8-K, Form 4, 10-K or 10-Q with the SEC. Free, no account needed.
Free foreverNo account requiredOne-click unsubscribe
Source: SEC EDGAR.